Tirzepatide (TZP) is a once-weekly GIP/GLP-1 receptor agonist for treating type 2 diabetes. In the SURPASS clinical trial program, TZP demonstrated significant HbA1c and body weight reductions versus placebo and active comparators. This post-hoc analysis assessed the relationship between HbA1c and body weight reductions with TZP. HbA1c and body weight data were analyzed by trial, due to differences in design, background therapy, and baseline characteristics of participants. Significant correlations between HbA1c and body weight changes were observed with TZP in SURPASS-2, -3, -4 (all doses), and -5 (TZP 5 mg only). Consistent reductions in HbA1c and body weight, were observed in the vast majority of participants treated with TZP at doses of 5, 10, or 15 mg.
